Psychedelic News and Analysis Made Simple for Investors

Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.

Track the entire psychedelic market

Track the entire psychedelic market

We’ve developed the first all encompassing index to track the public psychedelic marketplace.

Explore the Index

Just Some of the Data we Cover

Latest News

Market Research

The MindMed Chronicles: Part 2 of the Interview with Jake Freeman of Freeman Capital

The following is a continuation of all our recent MindMed coverage. Last week, we published the first conversation with Jake Freeman. Click here to watch part 1 of the Jake Freeman interview. Before that, it all began with a two-part interview with Dr. Scott Freeman in August. Click here to watch part 1 of the…

Silo Pharma Press

Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that CEO Eric Weisblum will present and host investor meetings at the 7th Annual Dawson James Small Cap Growth Conference being held Wednesday, October 12, 2022, at the Wyndham Grand Hotel in Jupiter, Florida. Presentation: The…

Optimind Pharma Corp Press

Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health

 Optimi Health Corp. (CSE: OPTI | OTCQX: OPTHF | FRA: 8BN), a leading Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, is applauding the government of Alberta’s decision to regulate some psychedelics for therapeutic use in the province. The proposed framework as…

Wellbeing-Digital-Sciences Press

Wellbeing Subsidiary KGK Science Announces Psilocybin Microdose Capsule Formulation to be Submitted to Health Canada for Phase 2A Trial

Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc, today announced that the Company has completed the CMC package to…

Creso Pharma Press

Creso Pharma Unit Completes Enrollment for Phase 2 Psychedelic Trial

Creso Pharma (ASX:CPH) Canadian subsidiary, Halucenex, completed the enrollment of patients for its phase 2 trial investigating the use of the psychedelic drug psilocybin in patients with treatment-resistant post-traumatic stress disorder. The study, slated to start on Oct. 12, recruited 20 patients with PTSD who are also afflicted with other mental health conditions, the medical…

Market Research

The Birth of Integrative Medicine

Once upon a time, the only medicines available to man came from plants. There were no scientists in labs researching compounds or pharmaceutical companies selling drugs. There were no organizations, like the FDA, overseeing the safety and efficacy of medicines that people were treated with. The modern western healthcare system was developed, and plant medicines…

Atai Press

Atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT

atai Life Sciences N.V. (Nasdaq: ATAI), which is developing VLS-01, a form of N,N-dimethyltryptamine (DMT) for the treatment of treatment-resistant depression (TRD), announced today the dosing of the first subject in their Phase 1 SAD trial of VLS-01. The trial is a randomized, double-blind, placebo-controlled study designed to evaluate the relative bioavailability of buccal versus IV…

Explore the Psychedelic Landscape

Learn more about the psychedelic companies changing the industry.